236 related articles for article (PubMed ID: 28715578)
21. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
22. Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.
Jo JK; Lee HS; Lee YI; Lee SE; Hong SK
Asian J Androl; 2015; 17(2):248-52. PubMed ID: 25432498
[TBL] [Abstract][Full Text] [Related]
23. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
24. Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States.
Weiner AB; Patel SG; Eggener SE
Urol Oncol; 2015 Apr; 33(4):164.e11-7. PubMed ID: 25624093
[TBL] [Abstract][Full Text] [Related]
25. Histologic upgrading in patients eligible for active surveillance on saturation biopsy.
Chung PH; Darwish OM; Roehrborn CG; Kapur P; Lotan Y
Can J Urol; 2015 Feb; 22(1):7656-60. PubMed ID: 25694015
[TBL] [Abstract][Full Text] [Related]
26. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
27. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
[TBL] [Abstract][Full Text] [Related]
28. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
29. Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients.
Ploussard G; Isbarn H; Briganti A; Sooriakumaran P; Surcel CI; Salomon L; Freschi M; Mirvald C; van der Poel HG; Jenkins A; Ost P; van Oort IM; Yossepowitch O; Giannarini G; van den Bergh RC;
Urol Oncol; 2015 Feb; 33(2):71.e1-9. PubMed ID: 25131660
[TBL] [Abstract][Full Text] [Related]
30. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
31. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
32. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
[TBL] [Abstract][Full Text] [Related]
33. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
34. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
35. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.
Filippou P; Welty CJ; Cowan JE; Perez N; Shinohara K; Carroll PR
Eur Urol; 2015 Sep; 68(3):458-63. PubMed ID: 26138041
[TBL] [Abstract][Full Text] [Related]
36. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
37. Perineural invasion status, Gleason score and number of positive cores in biopsy pathology are predictors of positive surgical margin following laparoscopic radical prostatectomy.
Yang R; Cao K; Han T; Zhang YF; Zhang GT; Xu LF; Lian HB; Li XG; Guo HQ
Asian J Androl; 2017; 19(4):468-472. PubMed ID: 27004537
[TBL] [Abstract][Full Text] [Related]
38. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
[TBL] [Abstract][Full Text] [Related]
39. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
40. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer.
King AC; Livermore A; Laurila TA; Huang W; Jarrard DF
Urol Oncol; 2013 Aug; 31(6):739-43. PubMed ID: 21816639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
